Change of EPO treatment from subcutaneous epoetin to intravenous epoetin or darbepoetin alpha;Estudio comparativo sobre el tratamiento de la anemia renal en el paciente en hemodiálisis: Cambio de vía de administración de epoetina alfa frente a conversión a darbepoetina

Nefrologia

Volumn 24, Issue 6, 2004, Pages 564-571

  Molina, M ^a   Garcia Hernandez M A ^a   Navarro, M J ^b   De Gracia, M C ^b   Ortuno T ^b  

^a Allergy Section   (Spain)

^b Centro de hemodiálisis Nefroclub Carthago   (Spain)

Author keywords

Darbepoetin alpha; Haemodialysis; Renal insufficiency; RHuEPO

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEPTIDE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT;

ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 13844296725     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Winearls CG, Oliver DO, Pippard MJ y cols.: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1: 1175-1178, 1986.
2. Valderrábano F: Anaemia management in chronic kidney disease patients: an overview of current clinical practice. Nephrol Dial Transplant 17 (Supl. 1): 13-18, 2002.
3. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC y cols.: Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (12): 992-1000, 1989.
4. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR y cols.: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (4): 548-554, 1995.
5. De Schoenmakere G, Lamiere N, Dhondt A y cols.: The haematopoictic effect of recombinant human erythropoietin in hemodialysis is independent of the mode of administration (iv or sc). Nephrol Dial Transplant 13: 1770-1775, 1998.
6. Taylor JF, Belch JJF, Fleming LW y cols.: Erythropoietin response and route of administration. Clin Nephrol 41 (5): 297-302, 1994.
7. Kaufman JS, Reda DJ, Fye CL y cols.: Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affair Comparative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 339 (9): 578-583, 1998.
8. Besarab A, Reyes CM, Homberger J: Meta-analysis of subcutaneous versus intravenous erythropoietin in maintenance treatment of anaemia in hemodialysis patients. Am J Kidney Dis 40 (3): 439-446, 2002.
9. Potter S: Human inmune response to recombinant human proteins. J Pharm Sci 90: 1-11, 2001.
10. Schellekens H: Inmunogenicity of therapeutics proteins: Clinical implications and future prospects. Clin Ther 24 (11): 1-21, 2002
11. Macdougall IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20 (4): 375-381, 2000.
12. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J y cols.: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 (11): 2392-2395, 1999.
13. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C y cols.: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60 (2): 741-747, 2001.
14. Macdougall IC, Matcham J, Gray SJ y cols: Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 18: 576-581, 2003.
15. Locatelli F y cols.: Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa al a reduced dose frecuency relative to, recombinant human erythropoietin (r-HuEPO). Nephrol Dial Transplant 18: 362-369, 2003.
16. Martínez Castelao A y cols.: Estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en diálisis. Nefrología 23 (2): 114-124, 2003.
17. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316 (2): 73-78, 1987.
18. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. Jama 263 (6): 825-830, 1990.
19. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 15 (Supl. 4): 1-76, 2000.
20. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C y cols.: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (1): 110-118, 2002.
21. Vanrenterghem Y, Barany P, Mann JF y cols.: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduce dose frequeney compared with rHuEPO in dialysis patients. Kidney Int 62: 2167-2175, 2002.
22. Molina M, García Hernández MA, Navarro MJ y cols.: Tratamiento de la anemia renal con administración una vez cada dos semanas de darbepoetina alfa en pacientes con insuficiencia renal crónica prediálisis previamente tratados con epoetina alfa. Nefrologia XXV (1): 44-49, 2004.
23. Egrie JC, Browne JK: Developement and characterisation of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3): 3-13, 2001.
24. Centres for Medicare and Medicaid Services: Payment for Epogen, Procrit, and Aranesp under OPPS. Centers for Medicare and Medicaid Services. CY 2003 hospital outpatient prospective payment system. http://www.cms.hhs.gov// regulations/hopps/changecy2003.asp
25. Macdougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3): 14-21, 2001.
26. Ibbotson T, Goa KL: Darbepoetin alfa. Drugs 61 (14): 2097-2104, 2001.